Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Change in Receivables (2021 - 2023)

Inhibikase Therapeutics (IKT) has 3 years of Change in Receivables data on record, last reported at -$79602.0 in Q3 2023.

  • On a quarterly basis, Change in Receivables fell 1191.93% to -$79602.0 in Q3 2023 year-over-year; TTM through Jun 2024 was -$79602.0, a 143.45% decrease, with the full-year FY2023 number at -$39881.0, down 200.0% from a year prior.
  • Change in Receivables reached -$79602.0 in Q3 2023 per IKT's latest filing, down from $15083.0 in the prior quarter.
  • Over the last five years, Change in Receivables for IKT hit a ceiling of $332774.0 in Q1 2021 and a floor of -$369099.0 in Q3 2021.
  • A 3-year average of $10012.8 and a median of $7290.0 in 2022 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: skyrocketed 226.87% in 2022, then crashed 1191.93% in 2023.
  • Tracing IKT's Change in Receivables over 3 years: stood at -$107341.0 in 2021, then surged by 226.87% to $136180.0 in 2022, then crashed by 158.45% to -$79602.0 in 2023.
  • Business Quant data shows Change in Receivables for IKT at -$79602.0 in Q3 2023, $15083.0 in Q2 2023, and $24638.0 in Q1 2023.